Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
CAS RN: 25316-40-9 | Product Number: D4193
Doxorubicin Hydrochloride
Purity: >95.0%(HPLC)
- Hydroxydaunorubicin Hydrochloride
Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
---|---|---|---|---|---|
25MG |
$56.00
|
9 | 19 | ≥100 |
|
100MG |
$140.00
|
39 | 5 | ≥100 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
Product Number | D4193 |
Purity / Analysis Method | >95.0%(HPLC) |
Molecular Formula / Molecular Weight | C__2__7H__2__9NO__1__1·HCl = 579.98 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Refrigerated (0-10°C) |
Condition to Avoid | Light Sensitive,Heat Sensitive |
Packaging and Container | 25MG-Glass Bottle with Plastic Insert (View image) |
CAS RN | 25316-40-9 |
Related CAS RN | 23214-92-8 |
Reaxys Registry Number | 4229251 |
PubChem Substance ID | 253660149 |
Merck Index (14) | 3439 |
MDL Number | MFCD00077757 |
Appearance | Light yellow to Brown powder to crystal |
Purity(HPLC) | min. 95.0 area% |
Specific rotation | +240 to +270 deg(C=0.1,MeOH) |
Specific Rotation | 248° (C=0.1,MeOH) |
Maximum Absorption Wavelength | 497(H2O) nm |
Solubility in water | Soluble |
Solubility (soluble in) | Tetrahydrofuran, Methanol |
Solubility (insoluble in) | Ether, Chloroform, Benzene, Acetone |
Pictogram | |
Signal Word | Warning |
Hazard Statements | H302 : Harmful if swallowed. H361 : Suspected of damaging fertility or the unborn child. H373 : May cause damage to organs through prolonged or repeated exposure. H351 : Suspected of causing cancer. |
Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
RTECS# | QI9295900 |
HS Number | 2932.99.7000 |
Reference
- Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells
References
- 1) Doxorubicin augments rAAV-2 transduction in rat neuronal cells
- 2) Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway
- 3) Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia
References
- Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events
- T. Bertani, A. Poggi, R. Pozzoni, F. Delaini, G. Sacchi, Y. Thoua, G. Mecca, G. Remuzzi, M. B. Donati, Lab. Invest. 1982, 46, 16.
- Adriamycin-induced chronic proteinuria: a structural and functional study
- M. P. O'Donnell, L. Michels, B. Kasiske, L. Raij, W. F. Keane, J. Lab. Clin. Med. 1985 106, 62.
- Effect of dietary protein restriction on renal purines and purine-metabolizing enzymes in adriamycin nephrosis in rats: a mechanism for protection against acute proteinuria involving xanthine oxidase inhibition
- G. M. Ghiggeri, F. Ginevri, G. Cercignani, R. Oleggini, A. Garberi, G. Candiano, P. Altieri, R. Gusmano, Clin. Sci. (Lond). 1990, 79, 647.
- Effect of enalapril on adriamycin-induced nephrosis
- Erlotinib preserves renal function and prevents salt retention in doxorubicin treated nephrotic rats
- Protective effects of sinomenine against doxorubicin-induced nephrosis in rats
References
- Adriamycin-induced cardiac damage in the mouse: a small-animal model of cardiotoxicity
- S. H. Rosenoff, H. M. Olson, D. M. Young, F. Bostick, R. C. Young, J. Natl. Cancer Inst. 1975, 55, 191.
- Experimental animal models of adriamycin cardiotoxicity
- J. H. Doroshow, G. Y. Locker, C. E. Myers, Cancer Treat. Rep. 1979, 63, 855.
- Adriamycin-induced cardiomyopathy. A rat model
- A. Czarnecki, A. Hinek, D. Sołtysiak-Pawluczuk, Pol. J. Pharmacol. Pharm. 1986, 38, 171.
- Chronic doxorubicin induced cardiomyopathy in rabbits: mechanical, intracellular action potential, and beta adrenergic characteristics of the failing myocardium
- Serial assessment of myocardial properties using cyclic variation of integrated backscatter in an adriamycin-induced cardiomyopathy rat model
- Improvement of doxorubicin induced cardiomyopathy in rats treated with insulin-like growth factor I
- Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure
- Doxorubicin dose for congestive heart failure modeling and the use of general ultrasound equipment for evaluation in rats Longitudinal in vivo study.
Reference
- The antiemetic effect of a novel tropisetron patch in anticancer agents-induced kaolin pica model using rats
References
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin
- Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
- The Power and Potential of Doxorubicin-DNA Adducts
- Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Articles/Brochures
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.